Full Press Release Details
Contact: Investor Contact:
Dr. Bernard Kasten Dianne Will
SIGA Technologies, Inc. Willstar Consultants, Inc.
Chief Executive Officer (518) 398-6222
(212) 672-9100 dwill@willstar.net
SIGA Technologies To Present at The Wall Street Analyst Forum in
New York City on November 30, 2004
New York, NY, November 24, 2004 - SIGA Technologies, Inc. (NASDAQ: SIGA),
announced today that Dr. Bernard Kasten, SIGA's Chief Executive Officer, will
present at The Wall Street Analyst Forum in New York City on November 30, at
11:40 AM. This conference is held at The Roosevelt Hotel located on 45th Street
Analysts and portfolio managers who wish to attend the presentation should
contact The Wall Street Analyst Forum at (802) 253-7596, or Dianne Will,
Investor Relations for SIGA Technologies, at (518) 398-6222 to request
additional information. A live webcast of this presentation will be available
via the Company's website at www.siga.com or
http://www.vcall.com/CEPage.asp?ID=89885. An archived presentation will be
available on the Company's website for thirty days.
About SIGA Technologies, Inc.
SIGA Technologies is applying bacterial genomics in the design and development
of novel products for the prevention and treatment of serious infectious
diseases, with an emphasis on products for biological warfare defense. SIGA has
the potential of becoming a significant force in the discovery of vaccine and
pharmaceutical agents to fight emerging pathogens. SIGA's product development
programs emphasize the increasingly serious problem of drug resistant bacteria
and emerging pathogens. SIGA's vaccine and drug platforms are based on its
pioneering research into the structure, function and processing of bacterial
surface proteins. SIGA is leveraging these platforms through multiple strategic
partners, including the National Institutes of Health and TransTech Pharma, Inc.
For more information about SIGA, please visit SIGA's Web site at www.siga.com.
This presentation contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended,
including statements regarding the efficacy of potential products, the timelines
for bringing such products to market and the availability of funding sources for
continued development of such products. Forward-looking statements are based on
management's estimates, assumptions and projections, and are subject to
uncertainties, many of which are beyond the control of SIGA. Actual results may
differ materially from those anticipated in any forward-looking statement.
Factors that may cause such differences include the risks that (a) potential
products that appear promising to SIGA or its collaborators cannot be shown to
be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA
or its collaborators will not obtain appropriate or necessary governmental
approvals to market these or other potential products, (c) SIGA may not be able
to obtain promised funding for its development projects or other needed funding,
and (d) SIGA may not be able to secure or enforce adequate legal protection,
including patent protection, for its products. More detailed information about
SIGA and risk factors that may affect the realization of forward-looking
statements, including the forward-looking statements in this
presentation, is set forth in SIGA's filings with the Securities and Exchange
Commission, including SIGA's Annual Report on Form 10-K for the fiscal year
ended December 31, 2003, and in other documents that SIGA has filed with the
Commission. SIGA urges investors and security holders to read those documents
free of charge at the Commission's Web site at http://www.sec.gov. Interested
parties may also obtain those documents free of charge from SIGA. SIGA does not
undertake to publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.